Adlai Nortye's Participation in an International Conference
Adlai Nortye Ltd. (NASDAQ: ANL), a forward-thinking biotechnology firm dedicated to pioneering cancer therapies, has announced its participation in a prestigious international conference focused on molecular targets and cancer treatments. This significant event will take place in Boston from October 22-26 in 2025, marking an important milestone for the company.
Details of the Presentation
During this conference, the company will present an oral talk focusing on their latest research. This is an incredible opportunity for Adlai Nortye to share its advancements directly with key industry leaders and peers.
Key Presentation Information
The details of the presentation are as follows:
Abstract Title: Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window.
Date and Time: Saturday, October 25, from 11:45 AM to 12:15 PM ET.
Session Title: Spotlight on Proffered Papers 3: Novel Therapeutic Agents.
About the Innovative AN4035
A focal point of the presentation will be AN4035, an innovative ADC designed to target CEACAM5 while utilizing a pan-RAS(ON) inhibitor to extend treatment efficacy for patients. This groundbreaking approach is indicative of Adlai Nortye's commitment to developing therapies that offer improved outcomes for cancer patients.
Upcoming Insights on AN4035
On October 22, 2025, prior to the presentation, the cornerstone data surrounding AN4035 will become available on the AACR portal. This release is anticipated to provide insights into the scientific rationale behind AN4035, thereby setting the stage for a deeper understanding of this therapeutic approach.
Overview of Adlai Nortye
Operating on a global scale, Adlai Nortye focuses on the development and commercialization of cancer therapies through its extensive R&D centers in both the U.S. and China. Their product pipeline is robust, with significant advancements in therapies that modulate immune responses and target RAS-driven cancers.
Innovative Drug Portfolio
The company is advancing a variety of innovative drug candidates, which includes their notable compounds: AN8025, a multifunctional protein targeting PD-1/L1, and AN4005, a unique oral small-molecule PD-L1 inhibitor. These therapies are designed to improve the treatment landscape for patients facing a myriad of cancer types.
Company Contact Information
For inquiries regarding the presentation or other corporate matters, you may contact Adlai Nortye's Investor Relations at Email: ir@adlainortye.com.
Frequently Asked Questions
What is the AACR-NCI-EORTC conference?
The AACR-NCI-EORTC conference is an influential international event focused on the latest developments in cancer research and therapeutic innovations.
What is AN4035?
AN4035 is a novel antibody-drug conjugate designed to target CEACAM5 and is equipped with a proprietary pan-RAS(ON) inhibitor payload.
When will Adlai Nortye present?
The company will present on October 25 from 11:45 AM to 12:15 PM ET during the conference.
How can I follow the updates on Adlai Nortye?
You can obtain updates by following their official announcements and releases shared prior to significant events.
Where are Adlai Nortye's R&D centers located?
The company's R&D centers are located in the United States and China, enabling a broad scope for discovery and development.
